Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9-valent HPV vaccination in female patients with recurrent respiratory papillomatosis
ChiCTR2500103158Phase 4Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- May 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human papillomavirus 9-valent vaccine in Laryngeal papilloma (RRP) (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Changes in the rate of tumor proliferation. Planned start May 2025; status: not yet recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
Laryngeal papilloma (RRP)
Beyond the preview
Go deeper on ChiCTR2500103158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103158.